Tell me about aztr and when should I buy it

Azitra, Inc. (AZTR) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. Here's an analysis to help you decide when to buy the stock:

1. Product Pipeline and Clinical Trials: Azitra has a promising product pipeline, including ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor-associated rash. The company is set to begin a first-in-human trial of ATR-12 in 2023. Recent preclinical data presented by Azitra suggest that ATR-12 shows potential for treating Netherton syndrome by significantly reducing IL-36γ, a pro-inflammatory cytokine.
2. Industry Position: Azitra operates within the biotechnology industry, which is known for its potential for high growth.

3. Stock Performance: The stock has experienced significant volatility, with a high weekly volatility of 81.40%. The stock's recent price movement may indicate short-term overvaluation, but long-term investors might see potential in the company's pipeline and industry position.

4. Technical Indicators: The stock's RSI (Relative Strength Index) is at 39.8, which is neither overbought nor oversold. The MACD (Moving Average Convergence Divergence) is at 0.17, indicating a potential upward momentum. The KDJ (Stochastic Oscillator) is at 4.3, suggesting an oversold condition.

5. Market Sentiment: The company's recent announcements of preclinical data and presentations at industry conferences indicate positive developments.
6. Valuation: Azitra's focus on precision dermatology and its innovative approach using genetically engineered bacteria could justify a higher valuation. However, investors should consider the company's stage of development and the potential risks associated with clinical trials and regulatory approvals.

Conclusion: Given the company's promising pipeline, industry position, and recent positive developments, Azitra could be a good long-term investment option. However, short-term investors should be cautious due to the stock's high volatility. For a long-term buy, consider a gradual approach, buying over a series of days or weeks to average the purchase price and reduce the impact of short-term volatility.